GSK, a UK-based biopharma, reported strong 2024 results, with a promising shift toward specialty medicines. Read why I ...

Revenue for Arexvy and Abrysvo fell sharply year over year in the fourth quarter due to narrower U.S. guidelines for their ...

While vaccine sales dropped, GSK raised its revenue guidance for 2031 with speciality medicines expected to drive that growth ...

Even as GSK’s RSV vaccine launch hits a serious slowdown, the British pharma has dialed up its long-term sales guidance once ...

The report provides insights into GSK's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.Dublin, Feb. 06, 2025 (GLOBE NEWSWIRE) ...

GSK reports better-than-expected Q4 earnings. It also announces a new share buyback program and raises the long-term sales outlook for 2031 by $2 billion.

We recently compiled a list of the 10 Companies Jump on Better Earnings, Outlook. In this article, we are going to take a ...

GSK (GSK) announced that new drug applications have been accepted for review by the China National Medical Products Administration and ...

GSK (LSE: GSK) has reported a 7% increase in full-year revenue for 2024, reaching £31.4 billion ($39.3 billion), slightly ...

GSK (LON: GSK) has issued an update which inevitably reflects the difficulties faced in the last year, while also providing a host of reasons to be more upbeat on future prospects. Concerns over the ...

J.P. Morgan analyst James Gordon maintained a Sell rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.40.

Pharma giant GSK surged to the top of the index as it missed forecasts slightly with its annual results, but raised its ...